Medical Licensing (MD/DO) · Independent exam preparation
ABIM Nephrology Certification: Clinical Reasoning Guide Study Guide
Practise electrolyte interpretation, kidney disease diagnosis, dialysis decisions, transplant assessment, and treatment safety across ABIM nephrology domains.
By CertMedbry · Updated 18 October 2026
Build decisions from physiology: distinguish water from solute disorders, interpret kidney injury patterns, select kidney-protective treatment, recognize dialysis indications, and investigate allograft dysfunction. This selective 60-concept guide follows the ten domains of ABIM’s January 2026 Nephrology Certification Examination blueprint. The official expanded outline defines the full examination scope, including topics beyond these lessons. The original questions and flashcards support physician subspecialty study and are independent of ABIM.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification pathway does this guide cover?
The official examination is ABIM’s Nephrology Certification Examination, identified in its blueprint as Certification Examination (CERT). The workbook label “ABIM - Subspecialty in Nephrology” refers to this examination. ABIM awards the physician subspecialty certification; eligibility requirements are governed by its nephrology certification policies.
How many questions are included, and do all questions count?
The January 2026 certification blueprint specifies up to 240 single-best-answer multiple-choice questions. Approximately 40 are new questions that do not count toward the examinee’s score. These are qualified figures, so the blueprint should not be converted into an exact guaranteed scored-question count.
ABIM Nephrology Blueprint — Certification Examination (CERT), January 2026
What question styles and clinical materials should candidates expect?
Most questions describe patient scenarios and assess diagnosis, test interpretation, treatment, prognosis, epidemiology, or clinically relevant pathophysiology. Clinical materials may include photographs, ultrasound images, angiograms, micrographs, radiographs, and electrocardiograms. The drills here are original four-option single-best-answer questions.
ABIM Nephrology Blueprint — Certification Examination (CERT), January 2026
What are the examination duration, delivery arrangements, and adaptivity?
ABIM lists approximately 10 hours overall, with four sessions of up to two hours and up to 60 questions each. Candidates share 100 total minutes of break time across three breaks; this is not 100 minutes per break. Registration begins through ABIM’s Physician Portal, followed by appointment scheduling with Pearson VUE. The cited instructions do not establish adaptive delivery, so adaptivity should not be inferred from the multiple-choice format.
ABIM — Register, Prepare and Take Your Nephrology Certification Exam
Which blueprint version applies, and is there a separate effective date?
This guide uses the certification blueprint dated January 2026, linked by ABIM and verified in October 2026. No separate implementation or effective date is stated in that document. ABIM reviews its blueprint annually and updates it as needed; actual examination content may vary.
ABIM Nephrology Blueprint — Certification Examination (CERT), January 2026 · ABIM — Blueprints
How is the official content distributed?
The published weights are Sodium and Water Abnormalities 8%; Acid-Base and Potassium Disorders 9%; Calcium, Phosphorus, and Magnesium Disorders and Stones 4%; Chronic Kidney Disease 22%; Hypertension 10%; Tubular, Interstitial, and Cystic Disorders 4%; Glomerular and Vascular Disorders 12%; Kidney Transplantation 11%; Pharmacology 5%; and Acute Kidney Injury and Intensive Care Unit Nephrology 15%. End-stage renal disease constitutes 11.5% of the whole examination within CKD. This guide and its short drills approximate the top-level proportions while covering every domain.
ABIM Nephrology Blueprint — Certification Examination (CERT), January 2026
Can the certification blueprint be replaced by an MOC or LKA outline?
Use the CERT outline for this certification examination. ABIM separately provides maintenance-of-certification assessment blueprints; those assessments and LKA are distinct from initial subspecialty certification. Their outlines, administration details, and preparation assumptions should not be substituted for CERT requirements.
ABIM — Blueprints · ABIM Nephrology Blueprint — Certification Examination (CERT), January 2026
How should publication dates of clinical guidelines be interpreted?
Clinical references retain their own publication dates. The guide uses KDIGO 2024 CKD recommendations, KDIGO 2021 blood-pressure guidance, the 2017 CKD-MBD update, and published KDIGO 2012 AKI criteria. At the October 2026 verification, KDIGO described the AKI update as being prepared for publication and a CKD focused update as underway. A blueprint dated 2026 does not make older clinical guidance a 2026 publication.
KDIGO — Acute Kidney Injury and Acute Kidney Disease · KDIGO — CKD Evaluation and Management · KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
This guide addresses the American Board of Internal Medicine’s Nephrology Certification Examination for physician subspecialty certification. It does not represent a general medical licensing examination, nursing credential, maintenance-of-certification assessment, or Longitudinal Knowledge Assessment.
Outline used: ABIM Nephrology Blueprint, Certification Examination (CERT), dated January 2026; verified through ABIM's currently linked certification blueprint on 2026-10-09. No separate effective date is stated. The workbook label 'ABIM - Subspecialty in Nephrology' maps to the official Nephrology Certification Examination; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Sodium and Water Abnormalities8%
1.How does tonicity organize the evaluation of hyponatremia?
A low sodium concentration does not always indicate hypotonic plasma. Hyperglycemia can lower measured sodium by drawing water extracellularly, while marked lipid or protein excess can produce pseudohyponatremia with some laboratory methods. Establish effective osmolality before applying a hypotonic-hyponatremia algorithm. Once hypotonicity is confirmed, urine osmolality and urine sodium help distinguish suppressed antidiuresis, persistent antidiuretic activity, and reduced effective circulating volume rather than relying on sodium concentration alone.
Apply it
A patient has sodium 126 mmol/L and marked hyperglycemia. Assess glucose-related hypertonicity before diagnosing SIAD. A second patient with similarly low sodium but low effective osmolality requires a hypotonic-hyponatremia evaluation using paired urine measurements.
Common pitfall: Treating every low sodium value as hypotonic hyponatremia can misclassify glucose-related water shifts or laboratory artifact and lead to an inappropriate fluid strategy.
Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia, 2014
2.Which findings support SIAD rather than another cause of hyponatremia?
SIAD requires hypotonic hyponatremia with urine that remains inappropriately concentrated, generally above 100 mOsm/kg, despite reduced plasma osmolality. Clinical euvolemia and urine sodium above 30 mmol/L support the diagnosis when salt intake is adequate. Adrenal, thyroid, pituitary, and significant renal insufficiency must be excluded, and recent diuretic use complicates interpretation. The decisive principle is inappropriate antidiuresis after competing explanations have been addressed, not an isolated elevated urine sodium.
Apply it
A euvolemic patient has low effective serum osmolality, urine osmolality 460 mOsm/kg, and urine sodium 58 mmol/L. Normal adrenal and thyroid assessment and absence of diuretics make SIAD a coherent explanation for the paired results.
Common pitfall: Adrenal insufficiency can resemble SIAD biochemically. Labeling the pattern SIAD before excluding endocrine causes risks missing a treatable disorder with different management needs.
Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia, 2014
3.Why can low solute intake produce hyponatremia despite dilute urine?
Water excretion depends on both urine dilution and the quantity of solute available for excretion. With very low protein and salt intake, even maximally dilute urine may not carry enough daily water to match intake. Urine osmolality at or below 100 mOsm/kg indicates substantially suppressed antidiuretic activity and favors excess water relative to solute over sustained SIAD. Restoring solute can abruptly increase water excretion, making sodium monitoring important during treatment.
Apply it
A patient eating little protein or salt drinks several liters daily and develops hypotonic hyponatremia with urine osmolality 75 mOsm/kg. The dilute urine directs attention to water intake and low solute availability rather than persistent antidiuresis.
Common pitfall: Dilute urine does not make hyponatremia harmless. Introducing food or saline may restore water clearance rapidly and accelerate correction beyond the intended trajectory.
Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia, 2014
4.How does desmopressin help distinguish central from nephrogenic diabetes insipidus?
First establish true hypotonic polyuria and distinguish it from glucose or other solute diuresis. Central diabetes insipidus reflects inadequate vasopressin secretion, so urine concentration increases substantially after desmopressin in complete disease. Complete nephrogenic diabetes insipidus reflects renal resistance and shows little concentrating response. Partial disorders and chronic primary polydipsia overlap, so results must be interpreted with plasma sodium, osmolality, and the supervised testing protocol rather than a response threshold in isolation.
Apply it
After pituitary surgery, a patient develops hypernatremia and large volumes of dilute urine. During supervised evaluation, urine osmolality rises markedly after desmopressin. That response supports deficient hormone secretion with preserved renal responsiveness rather than complete renal resistance.
Common pitfall: A modest desmopressin response cannot reliably separate every partial disorder. Chronic polydipsia and incomplete hormone deficiency can produce overlapping water-deprivation test results in practice.
5.How should a calculated free-water deficit guide hypernatremia treatment?
Estimated free-water deficit = TBW × [(current sodium / target sodium) − 1], where TBW is estimated current total body water in liters. This simplified estimate excludes ongoing losses and depends on body composition. Circulatory assessment, hypernatremia duration, and repeated sodium measurements determine the replacement plan. Reference: Yun et al., Evaluation and management of hypernatremia in adults, equation 5 and replacement discussion: https://pmc.ncbi.nlm.nih.gov/articles/PMC10175862/.
Apply it
TBW 30 L, current sodium 154 mmol/L, and eventual target 140 mmol/L give 30 × [(154 / 140) − 1] = 3 L. Continuing polyuria adds replacement needs.
Common pitfall: The deficit is an estimated volume, not a timed infusion prescription. Restore circulation when necessary and adjust water delivery for ongoing losses and the observed sodium trajectory.
Acid-Base and Potassium Disorders9%
6.How does the anion gap distinguish metabolic acidosis mechanisms?
Calculate the anion gap as sodium − (chloride + bicarbonate). An increased gap suggests accumulation of unmeasured anions, such as lactate, ketoanions, retained acids, or toxic metabolites. A normal-gap acidosis generally reflects bicarbonate loss or impaired renal acid excretion with relative chloride retention. Albumin contributes substantially to the normal gap, so hypoalbuminemia can conceal an important increase. Interpret the result against the laboratory reference range and the patient's clinical setting.
Apply it
With sodium 140, chloride 104, and bicarbonate 14 mmol/L, the anion gap is 22 mmol/L. This directs evaluation toward unmeasured acids. Marked hypoalbuminemia would make the uncorrected value underestimate the abnormality.
Common pitfall: A gap within the laboratory range does not exclude accumulated acids in hypoalbuminemia. Conversely, the gap identifies a pattern without establishing a specific toxin or disease.
7.How does Winter's formula reveal a mixed acid-base disorder?
For metabolic acidosis, expected arterial carbon dioxide tension is approximately 1.5 times bicarbonate plus 8, with a range of about 2 mm Hg on either side. A measured value above this range indicates additional respiratory acidosis; a lower value indicates additional respiratory alkalosis. Compensation limits the pH disturbance but does not erase its cause. Comparing measured with expected carbon dioxide helps recognize ventilatory failure or an additional respiratory stimulus that the bicarbonate alone cannot identify.
Apply it
Bicarbonate is 12 mmol/L, giving an expected carbon dioxide tension of 26 mm Hg, approximately 24–28. A measured value of 40 indicates inadequate ventilatory compensation and a superimposed respiratory acidosis requiring a separate explanation.
Common pitfall: A carbon dioxide tension within the population reference range can still be pathologically high during metabolic acidosis, when an appropriate compensatory response should lower it.
8.Why does type 4 renal tubular acidosis cause hyperkalemia?
Type 4 renal tubular acidosis commonly reflects inadequate aldosterone activity or reduced responsiveness to it. Reduced distal potassium secretion produces hyperkalemia, while impaired net acid excretion contributes to a normal-anion-gap metabolic acidosis. Diabetes, kidney disease, and medications affecting the renin-angiotensin-aldosterone system are useful contextual clues. Unlike classic hypokalemic distal RTA, urine can still become acidic, so a low urine pH does not exclude type 4 RTA or prove adequate ammonium excretion.
Apply it
A patient with diabetes taking an angiotensin receptor blocker has potassium 5.8 mmol/L and persistent hyperchloremic acidosis. Review aldosterone-related physiology and medications rather than rejecting type 4 RTA because urine pH is below 5.5.
Common pitfall: Urine pH measures free hydrogen concentration, not total acid excretion. Acidic urine can coexist with inadequate ammonium excretion and clinically important renal metabolic acidosis.
9.Which combination points to distal renal tubular acidosis?
Classic distal RTA impairs distal urinary acidification, producing normal-anion-gap metabolic acidosis despite an inappropriately high urine pH during systemic acidosis. Hypokalemia, hypocitraturia, calcium phosphate stones, and nephrocalcinosis strengthen the pattern. Reduced urinary citrate removes an inhibitor of calcium crystallization, while alkaline urine favors calcium phosphate precipitation. Interpret urine pH in context because infection with urease-producing organisms and other circumstances can also alkalinize urine without establishing distal RTA.
Apply it
A recurrent stone former has bicarbonate 16 mmol/L, potassium 3.0 mmol/L, urine pH 6.4, and no urinary infection. Hyperchloremic acidosis together with persistently alkaline urine makes defective distal acidification a focused diagnostic possibility.
Common pitfall: Alkaline urine alone does not diagnose distal RTA. Establish systemic metabolic acidosis and exclude urinary infection before attributing the pH to a tubular acidification defect.
NIDDK — Renal Tubular Acidosis · EAU Guidelines on Urolithiasis — Metabolic Evaluation and Recurrence Prevention
10.When does hyperkalemia require definitive potassium removal?
Severe hyperkalemia requires assessment of electrical toxicity, ongoing potassium release, kidney function, and response to treatment. Membrane stabilization and shifting potassium intracellularly address immediate danger but do not remove potassium from the body. When life-threatening hyperkalemia persists despite medical measures, or effective excretion is unavailable, kidney replacement therapy may be necessary. The decision depends on the clinical threat and treatment response rather than a creatinine threshold or the assumption that a temporary concentration decrease is definitive correction.
Apply it
An oliguric patient initially improves after intracellular potassium-shifting treatment, but potassium rebounds with recurrent electrocardiographic abnormalities. Persistent inability to eliminate potassium makes urgent kidney replacement therapy appropriate while immediate protective measures continue.
Common pitfall: A transient serum potassium decrease after shifting therapy can create false reassurance. Rebound is possible because total body potassium remains elevated and excretion may remain negligible.
KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
Calcium, Phosphorus, and Magnesium Disorders and Stones4%
11.How does PTH separate major mechanisms of hypercalcemia?
Confirm hypercalcemia using ionized calcium or appropriately interpreted total calcium, then assess PTH. Hypercalcemia should suppress PTH; an elevated or inappropriately normal PTH therefore supports a PTH-dependent process, commonly primary hyperparathyroidism. Suppressed PTH directs attention toward PTH-independent mechanisms such as malignancy, granulomatous disease, or vitamin D excess. Calcium and PTH may need repeat measurement when abnormalities are mild. In a stone former, hypercalcemia with unsuppressed PTH warrants evaluation of hyperparathyroidism rather than classification as uncomplicated idiopathic hypercalciuria.
Apply it
A recurrent calcium-stone former has repeatedly elevated serum calcium and PTH within the laboratory reference interval. Because PTH should be suppressed during hypercalcemia, the apparently normal hormone concentration is physiologically inappropriate and supports a PTH-dependent evaluation.
Common pitfall: A PTH-dependent pattern does not by itself distinguish primary hyperparathyroidism from every alternative. Familial hypocalciuric hypercalcemia remains a relevant differential before a surgical decision.
EAU Guidelines on Urolithiasis — Metabolic Evaluation and Recurrence Prevention
12.Why should calcium-stone prevention usually preserve normal dietary calcium?
Dietary calcium binds oxalate within the intestine, reducing oxalate absorption and subsequent urinary delivery. Indiscriminate calcium restriction can therefore increase calcium oxalate stone risk despite appearing intuitive. Prevention instead combines adequate fluid intake, normal dietary calcium, sodium moderation, and treatment directed by stone analysis and urine abnormalities. Hypercalcemia warrants evaluation for causes such as primary hyperparathyroidism. Dietary calcium and unnecessary calcium supplementation are different decisions and should not be treated as interchangeable exposures.
Apply it
A recurrent calcium oxalate stone former has severely restricted dairy intake and high urinary oxalate. Restore appropriate dietary calcium with meals while addressing fluid intake and sodium, rather than intensifying calcium restriction because the stone contains calcium.
Common pitfall: The calcium content of a stone does not justify eliminating dietary calcium. Prevention must account for intestinal oxalate binding and the measured urinary risk profile.
EAU Guidelines on Urolithiasis — Metabolic Evaluation and Recurrence Prevention
13.Why is urine alkalinization central to uric acid stone prevention?
Low urine pH shifts urate toward poorly soluble uric acid, so uric acid stones can occur without striking hyperuricosuria. Increasing urine volume and appropriately alkalinizing urine directly address this solubility problem. Urate-lowering treatment has a different role when excessive uric acid excretion or another indication is present. Cystine stone prevention also uses high fluid intake and alkalinization, but requires disease-specific targets and sometimes thiol therapy. Stone identity determines how urine chemistry guides treatment.
Apply it
A patient repeatedly forms uric acid stones with urine pH 5.0 and no major increase in uric acid excretion. Prioritize monitored urine alkalinization and fluid intake because acidity is the dominant measured crystallization driver.
Common pitfall: Urate lowering alone may leave persistently acidic urine untreated. Excessive alkalinization also has consequences, including increased calcium phosphate crystallization risk in susceptible patients.
EAU Guidelines on Urolithiasis — Metabolic Evaluation and Recurrence Prevention
Chronic Kidney Disease22%
14.What establishes chronic kidney disease rather than a transient abnormality?
CKD requires abnormalities of kidney structure or function present for at least three months with implications for health. A persistently reduced GFR below 60 mL/min/1.73 m² qualifies, as can markers of kidney damage such as albuminuria even when GFR is preserved. Establish chronicity from previous measurements, imaging, pathology, or clinical history. A single abnormal creatinine or albumin measurement cannot distinguish CKD from acute kidney disease and should prompt appropriate assessment and follow-up.
Apply it
An eGFR of 52 mL/min/1.73 m² appears during gastroenteritis, with no prior results. Reassess after recovery and investigate chronicity rather than immediately assigning CKD. Repeated low values spanning four months would support a chronic diagnosis.
Common pitfall: Waiting three months is not required before evaluating a dangerous abnormality. Chronicity determines the CKD label, while acute clinical findings determine immediate investigation and treatment.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
15.How does CGA classification improve CKD risk assessment?
Classify CKD by cause, GFR category, and albuminuria category, abbreviated CGA. GFR and albuminuria provide complementary prognostic information; the same eGFR can carry substantially different risk when albuminuria differs. A1 is below 30 mg/g, A2 is 30–300 mg/g, and A3 is above 300 mg/g. G1 and G2 alone do not establish CKD without another marker of kidney damage. Cause remains essential because it influences progression, treatment, and inherited or systemic implications.
Apply it
Two patients have eGFR 48 mL/min/1.73 m², but urine albumin-to-creatinine ratios are 12 and 650 mg/g. Both are G3a, yet the patient with A3 albuminuria has a different risk profile and stronger albuminuria-directed treatment considerations.
Common pitfall: Using eGFR alone discards prognostic information. Conversely, labeling isolated G2 function as CKD without persistent kidney damage overdiagnoses disease in some patients unnecessarily.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
16.How should uncertainty and change in eGFR be interpreted?
Creatinine reflects filtration and non-GFR determinants, particularly muscle mass. Severe muscle wasting can make creatinine-based eGFR falsely reassuring; combined creatinine-cystatin C estimation or measured GFR can improve important decisions. Cystatin C also has non-GFR influences. For serial assessment, KDIGO identifies an eGFR change exceeding 20% as beyond expected variability and warranting evaluation; after starting a hemodynamically active therapy, a reduction exceeding 30% warrants evaluation. These thresholds trigger investigation of volume, medications, obstruction, or disease activity rather than automatically proving progression.
Apply it
An eGFR fall from 50 to 36 mL/min/1.73 m² is a 28% decline and merits investigation when no planned treatment change explains it. In severe muscle wasting, first consider whether creatinine-based estimation adequately represents filtration before making a high-stakes dosing decision.
Common pitfall: Neither an alternative filtration marker nor a change threshold supplies the injury mechanism. Reversible AKI can occur on CKD, and biomarker discordance requires clinical interpretation.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
17.How should newly detected albuminuria be confirmed?
Urine albumin-to-creatinine ratio helps account for urine concentration and is preferred for evaluating albuminuria. Confirm an unexpected abnormal result, ideally with a first-morning specimen, because exercise, infection, menstruation, and other transient influences can affect measurement. Persistent albuminuria informs diagnosis, prognosis, and treatment even when eGFR is normal. A dipstick result is a screening observation rather than a complete quantitative characterization, and albumin testing may not capture every form of nonalbumin proteinuria.
Apply it
An athlete has a positive protein dipstick after strenuous exercise. Quantify albumin-to-creatinine ratio and repeat under suitable conditions. Persistent elevation on subsequent first-morning samples has a different significance from an isolated postexercise finding.
Common pitfall: A negative albumin-focused test does not exclude every protein disorder. Suspected monoclonal light-chain disease requires testing suited to the protein being sought clinically.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
18.Which adults with CKD have strong indications for an SGLT2 inhibitor?
KDIGO 2024 recommends SGLT2 inhibition for adults with CKD, eGFR at least 20 mL/min/1.73 m², and urine ACR at least 200 mg/g, or heart failure irrespective of albuminuria. A separate recommendation supports treatment in type 2 diabetes with CKD and eGFR at least 20. Benefits extend beyond glucose lowering. A small initial reversible eGFR decrease is generally not a reason to discontinue, while prolonged fasting, surgery, or critical illness may warrant temporary withholding.
Apply it
An adult without diabetes has eGFR 32 mL/min/1.73 m² and persistent ACR 480 mg/g. The kidney-protective indication does not require diabetes. Discuss treatment and precautions rather than rejecting eligibility because glucose levels are normal.
Common pitfall: The initiation threshold should not automatically become a stopping threshold. Conversely, ketoacidosis risk during prolonged fasting or severe illness requires attention despite kidney-protective benefit.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
19.How should kidney function and potassium be monitored after RAS inhibition?
ACE inhibitors and angiotensin receptor blockers lower intraglomerular pressure and can produce an early creatinine increase. Check blood pressure, creatinine, and potassium within two to four weeks after starting or increasing treatment, with timing tailored to risk. KDIGO advises continuation unless creatinine rises by more than 30% within four weeks. A larger increase prompts evaluation for contributors such as volume depletion, interacting drugs, or renovascular disease. Hyperkalemia can often be managed without immediately abandoning treatment.
Apply it
Creatinine rises from 1.6 to 1.9 mg/dL after an ACE inhibitor, an increase of about 19%. With stable blood pressure and acceptable potassium, this change alone does not meet the guideline threshold for discontinuation.
Common pitfall: The 30% boundary is not permission to ignore symptoms or severe hyperkalemia. Evaluate tolerability and reversible contributors alongside the percentage change in creatinine.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
20.How should inadequate delivered hemodialysis dose change the prescription assessment?
Kt/V relates dialyzer urea clearance, treatment time, and urea distribution volume. For thrice-weekly hemodialysis, KDOQI 2015 recommends a target single-pool Kt/V of 1.4 per session, with a minimum delivered value of 1.2. Investigate shortened treatments, actual blood flow, access dysfunction, and sampling when delivery is low. Urea clearance alone does not establish adequate volume or symptom control. Reference: KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update, guideline 3: https://www.sciencedirect.com/science/article/abs/pii/S0272638615010197.
Apply it
A patient with negligible residual function has repeated delivered single-pool Kt/V values of 1.0 after early session termination. Address lost treatment time and barriers to attendance, then reassess delivery and access performance.
Common pitfall: Single-pool and standard weekly Kt/V are different measures. Do not transfer a per-session threshold unchanged to another treatment frequency or assume satisfactory urea clearance proves euvolemia.
ABIM Nephrology Blueprint — Certification Examination (CERT), January 2026
21.When should maintenance dialysis begin, and how should preparation precede it?
Dialysis initiation depends on symptoms, signs, quality of life, preferences, GFR, and laboratory abnormalities. Indications include kidney-failure manifestations, medically resistant electrolyte or acid-base abnormalities, uncontrolled volume or blood pressure, and progressive nutritional deterioration despite intervention. An eGFR alone is insufficient. Earlier planning should compare transplantation, home and facility dialysis, and comprehensive conservative care, accounting for prognosis, support, treatment burden, and patient goals. Education, transplant referral, and access preparation require lead time before an emergency constrains the available choices.
Apply it
One patient with very low eGFR remains stable; another has refractory pulmonary edema and worsening uremic symptoms. Uncontrolled complications support starting treatment in the second patient, while both need an individualized plan reflecting feasible modalities and informed preferences.
Common pitfall: Waiting for a numerical threshold can delay needed treatment. Conservative kidney management is active treatment of symptoms and complications and should be explained as a legitimate option for selected patients.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
22.Why does a cluster of adverse dialysis events require assessment of shared water and equipment?
Dialysis water requires treatment and monitoring beyond ordinary drinking-water safety. Chlorine or chloramine breakthrough can injure patients; microbial contamination can also cause adverse reactions. A cluster of hemolysis or pyrogenic reactions should prompt assessment of shared water, dialysate, and equipment alongside individual causes. Hemolysis can also result from overheating, hypotonic dialysate, or mechanical blood-line injury. References: CDC Water Use in Dialysis, https://www.cdc.gov/dialysis-safety/hcp/recommendations-resources/water-use-in-dialysis.html; CDC hemolysis outbreak investigation, https://www.cdc.gov/Mmwr/preview/mmwrhtml/00053608.htm.
Apply it
Several patients develop hemolysis during the same shift. Stop suspected exposure and urgently investigate common water, dialysate, and circuit factors rather than attributing each event independently to the patient's underlying disease.
Common pitfall: A municipal supply that is safe to drink is not automatically safe for dialysis. A shared-event pattern does not prove chloramine toxicity; temperature, composition, and mechanical causes remain competing explanations.
ABIM Nephrology Blueprint — Certification Examination (CERT), January 2026
23.Why can aggressive fluid removal cause hypotension during hemodialysis?
Ultrafiltration removes fluid from the vascular compartment, which must be replenished from other compartments to maintain circulation. If removal exceeds vascular refill and compensatory capacity, blood pressure can fall and organ perfusion can suffer. Evaluate fluid gains, target weight, treatment time, medications, and alternative causes of instability. A patient may be extracellularly overloaded yet poorly tolerate rapid removal. The prescription should address both cumulative volume excess and the hemodynamic limits of an individual treatment.
Apply it
A patient arrives with a large interdialytic weight gain and repeatedly becomes hypotensive when that entire gain is removed during a short session. Reassess fluid intake and treatment duration rather than repeatedly pursuing the same rapid removal.
Common pitfall: Hypotension does not prove the patient has no total fluid excess. Extravascular overload and inadequate intravascular refill can coexist during dialysis treatment in practice.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD · KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
24.Which findings establish peritoneal dialysis-associated peritonitis?
ISPD 2022 defines peritonitis by at least two of three findings: compatible symptoms such as abdominal pain or cloudy effluent; effluent white-cell count above 100/µL after a dwell of at least two hours, with more than 50% neutrophils; and a positive effluent culture. Collect appropriate specimens promptly. In rapid-cycle automated PD, the neutrophil percentage is especially important because short dwell times can keep the absolute white-cell count low despite infection.
Apply it
A PD patient has abdominal pain, cloudy effluent, and 650 white cells/µL with 82% neutrophils after a three-hour dwell. Clinical and cellular criteria already support peritonitis; a pending culture does not prevent diagnosis.
Common pitfall: A negative initial culture does not exclude peritonitis when other criteria are met. Short automated-dialysis dwells also make an absolute cell-count cutoff less reliable.
ISPD Peritonitis Guideline Recommendations: 2022 Update on Prevention and Treatment
25.How should PTH trends guide CKD-MBD decisions across disease stages?
Declining kidney function alters phosphate handling and vitamin D metabolism, promoting secondary hyperparathyroidism. Interpret serial calcium, phosphate, and PTH together. In nondialysis CKD G3a–G5, optimal PTH is unknown; persistent or progressive elevation prompts evaluation of phosphate excess, hypocalcemia, and vitamin D deficiency. Routine calcitriol or vitamin D analog use is not recommended for all such adults, although selected severe progressive disease may warrant it. In dialysis, excessive suppression can suggest low-turnover bone disease and should trigger review of calcium exposure and PTH-lowering treatment.
Apply it
A nondialysis patient with one mildly elevated PTH needs a trend and assessment of modifiable stimuli before active vitamin D. A dialysis patient with very low PTH and recurrent hypercalcemia needs reassessment of suppressive treatment and calcium exposure.
Common pitfall: Nondialysis and dialysis PTH interpretations are not interchangeable. PTH is an imperfect marker of bone histology; consider bone biopsy when identifying the underlying disorder would change treatment.
26.Which findings suggest clinically important dialysis access dysfunction?
Persistent prolonged bleeding after cannulation, arm swelling, altered thrill or bruit, difficulty achieving prescribed blood flow, and unexplained falling dialysis dose can indicate access stenosis. Correlate clinical findings with access imaging and treat the causative significant lesion when appropriate. Loss of thrill raises concern for thrombosis and requires urgent assessment. An imaging abnormality without clinical dysfunction does not automatically justify preemptive intervention. Reference: KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update, clinical monitoring and access dysfunction guidance: https://www.kidney.org/sites/default/files/2026-07/2019-kdoqi-guideline-vascular-access.pdf.
Apply it
A fistula develops an altered thrill, repeated prolonged needle-site bleeding, and declining delivered clearance. Assess for a clinically significant access lesion rather than simply increasing the prescribed pump speed.
Common pitfall: Access dysfunction can reduce dialysis delivery even when prescribed time is unchanged. Imaging-only stenosis and symptomatic access dysfunction require different decisions.
ABIM Nephrology Blueprint — Certification Examination (CERT), January 2026
Hypertension10%
27.How does standardized blood-pressure measurement change interpretation?
Standardized office measurement controls preparation, positioning, rest, equipment, and repeated readings to reduce avoidable measurement error. KDIGO's intensive systolic target in adults with hypertension and nondialysis, nontransplant CKD is tied to this method, so routine hurried readings are not automatically interchangeable. A treatment decision should consider how the value was obtained before applying a trial-derived target. Proper cuff sizing and patient preparation are part of clinical interpretation because technical error can create apparent resistance or conceal inadequate control.
Apply it
A patient is measured immediately after walking into clinic, while talking, with an undersized cuff. Repeat using a standardized protocol before intensifying medication based on that isolated value or comparing it directly with an intensive treatment target.
Common pitfall: There is no universal correction factor that reliably converts every routine office reading into a standardized value. Repeat the measurement appropriately rather than subtracting a fixed number.
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD
28.How do out-of-office measurements distinguish white-coat and masked hypertension?
In untreated adults, white-coat hypertension requires elevated office blood pressure with normal out-of-office blood pressure under the applicable diagnostic thresholds. Masked hypertension requires normal office pressure with elevated out-of-office pressure. Elevation in both settings indicates sustained hypertension, even when home readings are lower than office readings. In treated patients, elevated office pressure with normal out-of-office pressure is termed white-coat uncontrolled hypertension; normal office pressure with elevated out-of-office pressure is masked uncontrolled hypertension. Home or ambulatory monitoring should complement standardized office measurements, using validated equipment and repeated readings.
Apply it
An untreated patient has repeated office readings averaging 156/92 mm Hg and validated home readings averaging 118/72 mm Hg, supporting white-coat hypertension. If home readings instead average 142/88 mm Hg, the lower home pressure remains hypertensive and supports sustained hypertension. Ambulatory monitoring can clarify discordance and assess sleep-period pressure.
Common pitfall: A white-coat effect means office pressure exceeds out-of-office pressure; that difference alone does not establish white-coat hypertension. Confirm that out-of-office pressure is actually normal, distinguish treated from untreated phenotypes, and avoid substituting a treatment target for a diagnostic threshold.
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD
29.How do KDIGO blood-pressure targets differ between nontransplant CKD and kidney transplantation?
KDIGO 2021 suggests systolic pressure below 120 mm Hg, when tolerated, for adults with hypertension and nondialysis, nontransplant CKD using standardized office measurement. For adult kidney transplant recipients, Practice Point 4.1 specifies a target below 130/80 mm Hg using standardized office measurement. Symptomatic postural hypotension, limited life expectancy, and individual circumstances may justify less intensive treatment. The below-120 systolic recommendation should not be transferred to transplant recipients, dialysis populations, or unstandardized readings.
Apply it
A nontransplant patient with standardized systolic pressure 126 mm Hg develops dizziness and a substantial standing pressure fall after escalation. Reassess tolerability. For a transplant recipient, assess systolic and diastolic control against the separate below-130/80 target.
Common pitfall: Nondialysis status alone does not identify the population for the below-120 target because transplant recipients can also be off dialysis. Specify transplant status and measurement method before applying the recommendation.
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD
30.What establishes resistant hypertension rather than undertreatment or pseudoresistance?
Resistant hypertension means above-goal pressure despite three complementary antihypertensive classes at maximum or maximally tolerated doses, commonly an ACE inhibitor or ARB, a long-acting calcium-channel blocker, and a diuretic. Controlled pressure requiring at least four agents also qualifies. Confirm adherence, accurate measurement, and sustained out-of-office elevation to exclude pseudoresistance. Then assess sodium intake, volume, interfering medicines, and secondary causes. Reference: AHA scientific statement, Resistant Hypertension: Detection, Evaluation, and Management: https://www.ahajournals.org/doi/pdf/10.1161/HYP.0000000000000084.
Apply it
A patient has high ambulatory pressure on three listed drugs but frequently misses the diuretic and takes submaximal doses. Establish adequate treatment exposure before diagnosing resistance. Another patient controlled only with four agents meets the controlled resistant-hypertension definition.
Common pitfall: Counting prescriptions without checking doses, complementary classes, adherence, and out-of-office pressure confuses undertreatment or a white-coat effect with resistance.
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD
31.Which aldosterone and renin pattern supports primary aldosteronism?
Primary aldosteronism is characterized by aldosterone production that is inappropriate for the degree of renin suppression. Screening interprets aldosterone, renin, and their relationship rather than relying on hypokalemia alone. Many affected patients are normokalemic. Potassium deficiency can suppress aldosterone and produce a misleading result, while medications and testing conditions also influence interpretation. A high ratio caused only by very low renin is insufficient without considering the aldosterone concentration and the assay-specific diagnostic framework.
Apply it
A hypertensive patient has suppressed renin and aldosterone that remains inappropriately elevated. This pattern supports autonomous mineralocorticoid activity even with normal potassium. Review medications and testing conditions before deciding how the result should guide further evaluation.
Common pitfall: Normal potassium does not exclude primary aldosteronism. Conversely, a ratio driven by an extremely low denominator should not override an aldosterone concentration inconsistent with the diagnosis.
Endocrine Society — Primary Aldosteronism Clinical Practice Guideline, 2025
32.How does aldosterone subtype influence treatment selection?
Treatment of primary aldosteronism depends on whether clinically relevant aldosterone excess is unilateral or bilateral and whether the patient wants and can undergo surgery. Unilateral disease may be treated with adrenalectomy, while bilateral disease and nonsurgical pathways generally use mineralocorticoid receptor antagonism. An adrenal nodule alone does not prove the source of hormone secretion; subtype evaluation may require adrenal venous sampling. Effective therapy addresses aldosterone-mediated risk as well as the measured blood pressure.
Apply it
A patient with confirmed primary aldosteronism has a unilateral adrenal nodule and wants surgery. Establish functional lateralization through the appropriate subtype pathway rather than assuming the visible nodule is necessarily the aldosterone-producing source.
Common pitfall: Incidental adrenal nodules can coexist with bilateral aldosterone production. Anatomical asymmetry alone can misdirect surgery if functional secretion has not been adequately established beforehand.
Endocrine Society — Primary Aldosteronism Clinical Practice Guideline, 2025
Tubular, Interstitial, and Cystic Disorders4%
33.Which losses identify Fanconi syndrome?
Fanconi syndrome is generalized proximal tubular dysfunction, causing inappropriate urinary loss of several normally reclaimed substances. Findings can include glucose despite normal blood glucose, phosphate wasting, aminoaciduria, urate loss, and bicarbonate loss producing proximal RTA. The combination distinguishes a broad proximal transport defect from isolated glycosuria or isolated distal acidification failure. Acquired medication-related causes and inherited disorders should be considered. Prolonged phosphate wasting can contribute to bone disease, making the associated solute pattern clinically consequential.
Apply it
A patient has normal serum glucose, glycosuria, hypophosphatemia, and hyperchloremic metabolic acidosis. The linked losses suggest proximal tubular dysfunction. Review relevant medication exposures and evaluate the wider proximal transport pattern rather than diagnosing diabetes from urine glucose.
Common pitfall: Glycosuria alone does not establish Fanconi syndrome, particularly during SGLT2 inhibitor treatment. Look for inappropriate losses involving additional proximal tubular solutes and bicarbonate.
34.When should ADPKD prompt intracranial aneurysm screening?
KDIGO 2025 recommends screening people with ADPKD who have a personal history of subarachnoid hemorrhage or a family history of intracranial aneurysm, subarachnoid hemorrhage, or unexplained sudden death, provided treatment would be feasible and life expectancy is reasonable. Screening decisions also involve informed discussion of benefits and consequences. Time-of-flight magnetic resonance angiography without gadolinium is the preferred screening method. Routine screening should not be inferred solely from the presence of kidney cysts.
Apply it
A person with ADPKD reports that a first-degree relative died from aneurysmal subarachnoid hemorrhage. Discuss screening and arrange the appropriate noncontrast vascular imaging pathway rather than ordering routine contrast-enhanced brain imaging solely because of CKD.
Common pitfall: A screening recommendation applies to an asymptomatic risk assessment. Sudden severe headache or neurological symptoms require urgent diagnostic evaluation rather than scheduling an elective screening study.
35.How should a medication-associated interstitial nephritis pattern be investigated?
Acute interstitial nephritis is an intrinsic kidney injury that can follow medication exposure and may produce sterile pyuria, white-cell casts, and variable proteinuria. Fever, rash, and eosinophilia are possible but are not required. Review the temporal medication history, exclude infection and other causes of AKI, and stop a plausible offending agent when appropriate. Kidney biopsy can clarify uncertain cases when the result would change management; no single urinary finding reliably establishes the diagnosis.
Apply it
Creatinine rises after a new medication, with sterile pyuria but no rash or eosinophilia. Keep interstitial nephritis in the differential, assess competing explanations, and consider biopsy if uncertainty would alter the treatment decision materially.
Common pitfall: Absence of the classic hypersensitivity features does not exclude interstitial nephritis. Urinary eosinophils also lack sufficient reliability to serve as a standalone diagnostic test.
KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury · Utility of Urine Eosinophils in the Diagnosis of Acute Interstitial Nephritis - PMC
Glomerular and Vascular Disorders12%
36.Which urine findings localize kidney injury to the glomerulus?
Hematuria with dysmorphic erythrocytes or red-cell casts, especially when accompanied by proteinuria and declining kidney function, supports glomerular injury. Red-cell casts indicate bleeding within the nephron and are a particularly important localization clue. The sediment pattern should trigger evaluation for inflammatory glomerular disease, with serological testing and biopsy selected according to clinical context. Microscopy identifies a compartment and pattern, but does not distinguish every immune, infectious, or vascular cause without additional evidence.
Apply it
A patient develops rising creatinine, hypertension, proteinuria, and red-cell casts. Prioritize a glomerular workup rather than attributing the hematuria to an incidental lower urinary tract source or assuming a bland hemodynamic kidney injury.
Common pitfall: Hematuria alone is less specific than the combined sediment and clinical pattern. Absence of an observed cast also does not rule out glomerular disease.
KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
37.When does suspected anti-GBM disease require treatment before confirmation?
Anti-GBM disease can rapidly injure glomerular and pulmonary capillary basement membranes. In a compatible pulmonary-renal syndrome, KDIGO advises starting treatment without delay when the diagnosis is suspected, even before confirmation is complete. Standard combined therapy uses plasma exchange to remove circulating antibodies, cyclophosphamide to reduce production, and glucocorticoids to suppress inflammation. Dialysis dependence does not justify withholding potentially lifesaving treatment when pulmonary hemorrhage is present. Selected patients without pulmonary hemorrhage and with irreversible kidney injury require a different assessment.
Apply it
A patient has rapidly progressive kidney failure, hemoptysis, hypoxemia, and strong suspicion of anti-GBM disease. Obtain urgent diagnostic studies while initiating the combined treatment pathway; pulmonary hemorrhage remains a treatment indication even if dialysis is already required.
Common pitfall: Poor expected kidney recovery does not eliminate the pulmonary indication for treatment. Waiting for a biopsy result can allow life-threatening lung injury to progress rapidly.
38.How can anti-PLA2R antibodies change membranous nephropathy diagnosis?
In a patient with nephrotic syndrome and positive anti-PLA2R antibodies, membranous nephropathy can often be diagnosed without a kidney biopsy. The antibody identifies an important disease-specific immune association, but the broader clinical evaluation still matters. Assess for associated conditions and consider biopsy when atypical features, unexplained kidney dysfunction, or other findings could change management. Antibody positivity does not independently establish the need for immunosuppression, which depends on risk and the clinical course.
Apply it
An adult has nephrotic syndrome, positive anti-PLA2R antibodies, and no atypical features. A nonbiopsy diagnosis may be appropriate, while assessment for associated conditions and risk of progression continues before selecting supportive treatment alone or immunosuppression.
Common pitfall: A disease-specific antibody can support diagnosis without settling every management question. Do not equate a positive result with automatic high-risk disease or immediate immunosuppressive treatment.
39.Why does suspected adult minimal change disease usually require biopsy?
Adult nephrotic syndrome has several competing causes, and clinical features alone do not reliably establish minimal change disease. Kidney biopsy provides the diagnosis, typically showing relatively unremarkable light microscopy with diffuse podocyte foot-process effacement on electron microscopy. Once established, adult minimal change disease is generally treated initially with glucocorticoids unless contraindications or special circumstances change the approach. Medication exposure and associated conditions remain relevant because the histological pattern can occur in both primary and secondary settings.
Apply it
An adult develops abrupt edema, heavy proteinuria, and hypoalbuminemia. Although minimal change disease is plausible, arrange diagnostic evaluation including biopsy rather than transferring a childhood empirical-treatment approach directly to an adult with an unclassified nephrotic syndrome.
Common pitfall: Normal-appearing glomeruli on light microscopy do not mean there is no glomerular disease. Electron microscopy is central to recognizing the podocyte injury pattern.
KDIGO 2021 — Key Takeaways for Minimal Change Disease in Adults
40.When does a nephritic presentation require urgent evaluation for ANCA-associated vasculitis?
Rapidly declining kidney function with glomerular hematuria and compatible systemic findings warrants assessment for small-vessel vasculitis, including MPO- and PR3-ANCA testing and kidney biopsy. In a rapidly deteriorating patient with a compatible presentation and positive MPO- or PR3-ANCA, waiting for biopsy should not delay treatment. Initial therapy generally combines glucocorticoids with rituximab or cyclophosphamide. Reference: KDIGO 2024 ANCA-Associated Vasculitis Guideline, Practice Point 9.1.1 and Recommendation 9.3.1.1: https://kdigo.org/wp-content/uploads/2024/05/KDIGO-2024-ANCA-Vasculitis-Guideline-Update.pdf.
Apply it
Creatinine rises rapidly in a patient with red-cell casts, pulmonary findings, and positive MPO-ANCA. Arrange urgent tissue assessment and treatment while evaluating infection and other mimics.
Common pitfall: ANCA positivity alone does not establish active vasculitis, and negative ANCA does not exclude it. The clinical syndrome and pathology remain essential to diagnosis and prognosis.
KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
41.How does primary versus secondary FSGS classification determine treatment?
FSGS is a biopsy lesion with different mechanisms. Nephrotic syndrome, diffuse foot-process effacement, and absence of secondary or genetic explanations support primary FSGS. Secondary disease may reflect adaptive stress, reduced nephron mass, or another identifiable cause and generally receives cause-directed and antiproteinuric supportive care. KDIGO advises against immunosuppression for secondary FSGS and FSGS of undetermined cause without the primary nephrotic phenotype. Interpret protein excretion together with serum albumin, presentation, electron microscopy, and potential inherited or adaptive causes.
Apply it
Abrupt nephrotic syndrome with diffuse effacement supports primary disease after alternatives are excluded. Severe obesity with gradual proteinuria, preserved albumin, and adaptive biopsy findings instead favors supportive care, including blood-pressure control and treatment of the adaptive driver.
Common pitfall: Nephrotic-range protein excretion is not synonymous with the complete nephrotic syndrome. The shared lesion name does not justify the same immunosuppressive treatment for every patient.
42.How should thrombotic risk be assessed in membranous nephropathy?
Nephrotic membranous nephropathy carries substantial venous thromboembolic risk, particularly with severe hypoalbuminemia. The KDIGO prophylaxis algorithm uses serum albumin below 20 g/L when measured by bromocresol purple, versus below 25 g/L when measured by bromocresol green, to identify patients needing individualized venous-thrombosis versus bleeding-risk assessment. These correspond to 2.0 and 2.5 g/dL, respectively. Crossing an assay-specific threshold does not automatically mandate anticoagulation: additional thrombotic factors, bleeding history, kidney function, and patient preferences influence the decision.
Apply it
A patient with nephrotic membranous nephropathy has albumin 22 g/L measured by bromocresol green. Because 22 is below 25 g/L, assess whether prophylactic anticoagulation offers more benefit than bleeding harm. A recent major gastrointestinal bleed may outweigh that benefit. A reported value of 22 g/L measured by bromocresol purple does not cross its 20 g/L threshold; the assay must therefore be identified before applying the algorithm.
Common pitfall: Do not interchange albumin thresholds across assays or interpret a value above the threshold as proof of negligible thrombosis risk. Prophylaxis concerns prevention before an event; documented thrombosis requires a separate therapeutic anticoagulation assessment.
Kidney Transplantation11%
43.When does unexplained allograft dysfunction require biopsy?
Persistent unexplained elevation of creatinine in a kidney transplant recipient is an indication for allograft biopsy after assessing reversible or structural explanations. Evaluate volume status, obstruction, medication exposure, drug concentrations, and infection as appropriate. Rejection, calcineurin inhibitor toxicity, viral injury, and recurrent disease can overlap clinically but require different management. Biopsy helps distinguish mechanisms rather than allowing a creatinine rise alone to dictate whether immunosuppression should be increased or decreased without adequate diagnostic evidence.
Apply it
A stable transplant recipient develops persistent creatinine elevation despite correction of volume depletion, a nonobstructed ultrasound, and an acceptable tacrolimus level. Proceed toward allograft biopsy rather than assuming the drug level excludes clinically important graft pathology.
Common pitfall: A therapeutic tacrolimus concentration does not exclude rejection or other allograft disease. Empirical immunosuppression changes can worsen infection or delay treatment of an alternative mechanism.
44.When should maintenance immunosuppression be reduced for BK polyomavirus after kidney transplantation?
Immunosuppression permits BK polyomavirus replication and allograft injury; reducing maintenance immunosuppression allows recovery of antiviral immune control. The 2024 consensus supports reduction for plasma BK DNAemia of 1000–10000 copies/mL on two measurements within 2–3 weeks. A single measurement above 10000 copies/mL or biopsy-proven BK nephropathy supports reduction directly. Validated assay-equivalent results may be used when laboratories report different units. Reduction is the primary treatment in recipients without high immunologic risk or concurrent acute rejection; either complication requires an individualized strategy balancing viral injury against rejection.
Apply it
A recipient without recent rejection has plasma BK loads of 3200 and 4800 copies/mL two weeks apart using the same assay. These results support supervised, stepwise immunosuppression reduction with serial viral-load and graft-function monitoring. A single result of 18000 copies/mL supports reduction without waiting for another qualifying result. With high immunologic risk or suspected concurrent rejection, allograft biopsy can help direct the competing treatment decisions.
Common pitfall: Do not abruptly stop all immunosuppression or automatically intensify it for rising creatinine. BK nephropathy and rejection can both impair graft function but require different responses. Follow trends with a consistent assay and specimen type; copies/mL and IU/mL require assay-specific equivalence rather than an assumed universal conversion.
Second International Consensus Guidelines on BK Polyomavirus in Kidney Transplantation, 2024
45.How does biopsy guide treatment of suspected transplant rejection?
Biopsy identifies the rejection mechanism and the extent of active injury versus chronic damage. Acute T-cell-mediated cellular rejection is initially treated with corticosteroids, which suppress inflammatory signaling and lymphocyte activation. Steroid-resistant or recurrent cellular rejection can require lymphocyte-depleting treatment, such as antithymocyte globulin, to reduce the lymphocytes driving graft injury. Acute antibody-mediated rejection can require plasma exchange and intravenous immunoglobulin (IVIG): plasma exchange removes circulating antibodies, while IVIG modulates antibody-mediated immune injury. These approaches may be combined with other immunosuppressive treatment according to the lesion and clinical severity. KDIGO's antibody-mediated rejection recommendations rest on limited-quality evidence; they do not establish one universally superior regimen. Chronic active rejection combines ongoing immune injury with established structural damage, so treatment of an acute episode cannot be assumed to reverse chronic scarring.
Apply it
A recipient with rising creatinine has a biopsy showing acute T-cell-mediated rejection without antibody-mediated features. Initial corticosteroid treatment follows that diagnosis; persistent dysfunction despite treatment warrants reassessment, often including repeat biopsy, before escalation to lymphocyte-depleting therapy. Alternatively, biopsy-confirmed acute antibody-mediated rejection, interpreted with donor-specific antibodies and other diagnostic criteria, supports considering plasma exchange plus IVIG. Thus, similar creatinine elevations lead to different treatment choices because the tissue identifies different immune mechanisms.
Common pitfall: Donor-specific antibodies alone do not establish antibody-mediated rejection or automatically justify plasma exchange. Conversely, corticosteroids alone may inadequately address antibody-mediated injury. Distinguish acute active injury from chronic active disease: established fibrosis and transplant glomerulopathy are structural damage, not simply an acute inflammatory episode. Treatment decisions must weigh potentially reversible activity against chronic damage and the infection risks of intensified immunosuppression.
46.Why does new proteinuria after transplantation require investigation?
New proteinuria can signal allograft glomerular injury, including recurrent or de novo disease and transplant-related pathology. It should not be dismissed because creatinine remains stable, since filtration measurements and glomerular permeability provide different information. Quantify the abnormality, review the original kidney disease and transplant history, and assess competing causes. KDIGO recommends allograft biopsy for new-onset proteinuria and for unexplained substantial proteinuria. Establishing the lesion can change treatment and help define prognosis before advanced functional decline develops.
Apply it
A recipient develops persistent new albuminuria while creatinine remains near baseline. Quantify and investigate the protein loss, review recurrence risks, and consider allograft biopsy rather than waiting for a simultaneous creatinine increase to validate the finding.
Common pitfall: Stable creatinine does not establish a healthy allograft. Treating proteinuria as only a nonspecific laboratory nuisance can delay recognition of recurrent or transplant-associated glomerular disease.
47.Which vaccination principle matters during transplant immunosuppression?
Immunosuppression can reduce vaccine responses and increase the hazards of live vaccines. Tacrolimus prescribing information advises avoiding live vaccines during treatment, while transplant guidance supports appropriate inactivated vaccination with timing informed by the transplant course. Review immunization status before transplantation whenever possible, when responses may be more reliable and live-vaccine options can be assessed safely. Post-transplant vaccination decisions depend on vaccine type and immune status, so a blanket assumption that every vaccine is contraindicated is also incorrect.
Apply it
A tacrolimus-treated recipient asks about a live attenuated vaccine. Recognize the live-vaccine precaution and coordinate an appropriate alternative or specialist plan. Separately review indicated inactivated vaccines rather than abandoning preventive immunization altogether during follow-up.
Common pitfall: A live-vaccine restriction should not be generalized to all vaccines. Vaccine type, timing, and immune status determine the appropriate preventive strategy after transplantation clinically.
DailyMed — Tacrolimus Capsules Prescribing Information · KDIGO 2009 Kidney Transplant Recipient Guideline — Summary
48.When should transplant candidate assessment begin, and what can change readiness?
Refer potential candidates at least 6–12 months before anticipated dialysis to permit evaluation, living-donor work-up, and possible preemptive transplantation. Assess cardiovascular disease, infection, malignancy, frailty, psychosocial needs, and recurrence risks. Age alone should not exclude a candidate. Active infections generally require treatment before transplantation; hepatitis C has a distinct pathway. Reference: KDIGO 2020 Transplant Candidate Guideline: https://kdigo.org/wp-content/uploads/2018/08/KDIGO-Txp-Candidate-GL-FINAL.pdf. Cardiovascular and metabolic risk management must continue after transplantation despite satisfactory graft function.
Apply it
A patient approaching kidney failure has a potential living donor but untreated bacterial infection. Begin coordinated evaluation now, treat the infection before transplantation, and allow time for donor assessment rather than waiting for an emergency dialysis start.
Common pitfall: Referral, suitability assessment, and readiness for surgery are different decisions. Neither age alone nor the availability of a willing donor settles candidacy or eliminates the need for donor evaluation.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD · KDIGO 2009 Kidney Transplant Recipient Guideline — Summary
Pharmacology5%
49.Why are NSAIDs especially hazardous during dehydration?
During reduced effective circulating volume, kidney perfusion becomes more dependent on compensatory mechanisms, including prostaglandin-mediated support of afferent blood flow. NSAIDs inhibit prostaglandin synthesis and can precipitate hemodynamic AKI in this setting. Risk is greater when dehydration coexists with CKD or other medications affecting renal hemodynamics and volume. Medication review during vomiting, diarrhea, or poor intake should therefore include nonprescription pain remedies, since patients may not recognize them as kidney-relevant exposures when reporting current treatment.
Apply it
A patient with CKD develops vomiting and poor intake, then starts ibuprofen for body aches. Identify the combination of dehydration and NSAID exposure as an avoidable AKI risk and review all prescribed and nonprescription medicines.
Common pitfall: Over-the-counter availability does not imply kidney safety. A previously tolerated NSAID can become hazardous when an intercurrent illness changes circulating volume and renal perfusion.
NIDDK — Keeping Kidneys Safe: Smart Choices about Medicines · KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
50.How do CYP3A interactions alter tacrolimus exposure?
Tacrolimus is metabolized through CYP3A pathways. Inhibitors can increase exposure and toxicity, while inducers can lower exposure and increase rejection risk. Starting or stopping an interacting medication therefore requires anticipatory review, drug-level monitoring, and individualized dose adjustment. A stable historical dose does not guarantee stable exposure after a new antimicrobial or other interacting agent is introduced. Interpret trough concentrations together with sampling timing, renal function, symptoms, and the complete medication list rather than changing doses from an isolated result.
Apply it
A recipient's tacrolimus concentration rises after a potent CYP3A inhibitor is started. Recognize impaired metabolism as a plausible cause, assess toxicity, and coordinate monitoring and dose adjustment rather than attributing the change to worsening kidney clearance alone.
Common pitfall: Stopping an inhibitor can reverse the interaction and lower tacrolimus exposure. Monitoring must cover both introduction and withdrawal of interacting treatment to reduce underimmunosuppression risk.
51.Which drug properties limit removal by dialysis?
Dialytic removal depends on access of drug to plasma water, molecular characteristics, protein binding, distribution, and the dialysis technique. Extensive binding and distribution outside the accessible plasma compartment can make extracorporeal removal ineffective. Tacrolimus provides a clinically important example: prescribing information states that it is not expected to be dialyzable to a significant extent because of its binding and solubility characteristics. Kidney failure alone does not establish that dialysis will remove a medication or correct its toxicity.
Apply it
A tacrolimus-treated patient has excessive exposure and AKI. Dialysis may be indicated for a separate life-threatening electrolyte or fluid complication, but it should not be expected to clear tacrolimus substantially as the primary toxicity treatment.
Common pitfall: A drug causing kidney injury is not necessarily dialyzable. Separate the indication to support failed kidney function from the question of extracorporeal toxin removal.
Acute Kidney Injury and Intensive Care Unit Nephrology15%
52.What changes meet the published KDIGO definition of AKI?
KDIGO 2012 defines AKI by a creatinine increase of at least 0.3 mg/dL within 48 hours, an increase to at least 1.5 times baseline known or presumed within seven days, or urine output below 0.5 mL/kg/hour for six hours. Either creatinine or urine output can establish the syndrome. The criteria identify an acute functional change, not its mechanism. Establish timing and baseline carefully, then investigate hemodynamic, intrinsic, and obstructive explanations appropriate to the patient's presentation.
Apply it
Creatinine increases from 0.8 to 1.1 mg/dL in 36 hours. Although the final value may appear near a laboratory reference range, the absolute increase meets the published AKI definition and warrants clinical evaluation.
Common pitfall: A creatinine value within the laboratory range can still represent AKI. Comparing only the final number with a population reference interval misses meaningful individual change.
KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
53.How should discordant creatinine and urine-output AKI stages be reconciled?
Assign the highest KDIGO stage met by either criterion. Stage 2 includes creatinine 2.0–2.9 times baseline or urine output below 0.5 mL/kg/hour for at least 12 hours. Adult stage 3 includes creatinine at least three times baseline; an increase to at least 4.0 mg/dL, provided the acute change satisfies the AKI definition; initiation of kidney replacement therapy; urine output below 0.3 mL/kg/hour for at least 24 hours; or anuria for at least 12 hours. These are alternative pathways, not requirements that must all coexist.
Apply it
A patient's creatinine doubles, but accurately measured urine output remains 0.2 mL/kg/hour for 24 hours. The urine-output criterion establishes stage 3 despite a creatinine ratio that alone meets stage 2. Creatinine rising acutely from 3.6 to 4.1 mg/dL in 48 hours also meets stage 3.
Common pitfall: Stable chronic creatinine above 4.0 mg/dL does not establish AKI. Urine-output staging also requires reliable measurement and the specified duration.
KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
54.How does hemodynamic AKI differ from established tubular injury?
Hemodynamic AKI initially reflects inadequate filtration pressure or perfusion without necessarily implying structural tubular damage. Prolonged or severe ischemia can progress to acute tubular injury, so these mechanisms can evolve and coexist. History, examination, urine sediment, hemodynamic assessment, and response to appropriate correction help distinguish them. Fluid administration is useful when intravascular depletion is present, but persistent AKI in a congested patient should not trigger repeated fluid loading simply because the initial problem was called prerenal.
Apply it
After gastrointestinal losses, a patient has clinical volume depletion and rising creatinine. Restore circulation and reassess. Continued oliguria with granular casts after perfusion improves suggests tubular injury rather than an automatic need for repeated additional fluid boluses.
Common pitfall: A hemodynamic label is not proof that more fluid is always beneficial. Congestion and reduced effective perfusion can coexist, requiring reassessment of the circulation.
KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
55.Which sediment findings support acute tubular injury?
Renal tubular epithelial cells and granular casts, often described as muddy brown, support acute tubular injury in the appropriate setting. They contrast with red-cell casts suggesting glomerular bleeding and white-cell casts that may occur with interstitial inflammation or infection. Microscopy adds anatomical information that serum creatinine cannot provide. A compatible ischemic or nephrotoxic exposure strengthens the interpretation, but the absence of a characteristic sediment does not exclude tubular injury or remove the need to investigate competing mechanisms.
Apply it
Following sustained hypotension, a patient develops AKI with abundant granular casts and tubular epithelial cells. This supports tubular injury and changes the interpretation of persistent dysfunction after blood pressure recovers, compared with a purely functional reduction in filtration.
Common pitfall: Sediment findings should be integrated with timing and clinical context. A bland sample does not reliably exclude intrinsic injury, especially when sampling or microscopy quality is limited.
KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
56.Why should fractional sodium excretion be interpreted cautiously?
Fractional sodium excretion estimates the fraction of filtered sodium appearing in urine, but it is not a direct test of tissue injury. Diuretics can increase sodium excretion, while some intrinsic kidney disorders can retain sodium. CKD, timing, and the broader clinical state further affect interpretation. Use urine indices as supporting observations alongside sediment, hemodynamics, medication exposure, and trajectory. Neither a low value nor a high value should independently determine whether a patient receives fluids or has intrinsic AKI.
Apply it
A patient recently received a loop diuretic and has an elevated fractional sodium excretion. Do not use that result alone to exclude reduced effective circulating volume. Examine the circulation and sediment and reassess the evolving clinical picture.
Common pitfall: Substituting another urine index does not eliminate all uncertainty. No isolated fractional-excretion measurement reliably replaces a mechanism-based clinical assessment across every AKI setting encountered.
KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
57.When should postrenal obstruction remain a priority in AKI?
Consider obstruction when AKI occurs with retention symptoms, pelvic or retroperitoneal disease, stones, a solitary functioning kidney, or other relevant risks. Bladder assessment and kidney imaging help identify the level and consequences of obstruction. Bilateral obstruction, or obstruction affecting a solitary functioning kidney, can markedly reduce total filtration. Early obstruction may not produce striking dilation, so imaging must be interpreted with timing and clinical suspicion. Relief of obstruction should be followed by monitoring for postobstructive fluid and electrolyte losses.
Apply it
An older patient has new oliguria, suprapubic fullness, and rising creatinine. Assess bladder retention promptly and evaluate the upper tract as indicated rather than assuming age and reduced intake explain a purely hemodynamic AKI.
Common pitfall: Urine production does not exclude partial obstruction. A reassuring early image also requires reconsideration when the clinical likelihood remains high and kidney dysfunction persists unexplained.
KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
58.Which complications require emergency kidney replacement therapy in AKI?
KDIGO recommends emergency kidney replacement therapy for life-threatening disturbances of fluid, electrolyte, or acid-base balance. Examples include refractory hyperkalemia, severe uncontrolled acidosis, and pulmonary edema that cannot be managed adequately by other measures. Uremic complications also influence the decision. Assess the overall clinical context and laboratory trends rather than using a single urea or creatinine cutoff. Temporary medical stabilization can proceed while definitive therapy is arranged, but should not obscure a persistent inability to control the dangerous abnormality.
Apply it
An oliguric patient has worsening hypoxemia from pulmonary edema despite appropriate medical treatment. The uncontrolled respiratory consequence of fluid accumulation supports emergency kidney replacement therapy even if creatinine is lower than in another clinically stable patient.
Common pitfall: High creatinine alone is not an emergency indication, and a modest value does not protect against an emergency. The uncontrolled physiological complication determines urgency.
KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
59.When is continuous kidney replacement therapy favored over intermittent dialysis?
KDIGO suggests continuous therapy rather than standard intermittent treatment for hemodynamically unstable patients. Slower, sustained solute and fluid removal can be better tolerated when circulation cannot accommodate rapid shifts. Continuous therapy is also favored in AKI with acute brain injury, increased intracranial pressure, or generalized brain edema. Modality selection depends on the patient's physiology, treatment objectives, resources, and expertise. Continuous and intermittent techniques are complementary tools, and continuous treatment should not be presented as universally superior for every patient.
Apply it
A patient requiring escalating vasopressors has an urgent need for fluid and solute control. Continuous therapy offers a more gradual approach than conventional intermittent dialysis, while prescription and monitoring remain essential to avoid excessive fluid removal.
Common pitfall: Continuous treatment does not eliminate hypotension or guarantee better survival. Its advantage in selected patients concerns physiological tolerability and controlled delivery rather than universal outcome superiority.
KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
60.What role should diuretics play in established AKI?
Diuretics do not reverse established tubular injury and should not be used simply to convert oliguric AKI into a higher-output state or to prevent AKI. KDIGO supports their use for management of volume overload when clinically appropriate. A rise in urine output after a diuretic does not establish recovery of filtration or remove a dialysis indication. Monitor the patient's circulation, electrolytes, fluid balance, and underlying cause, separating symptomatic fluid management from treatment of the kidney injury itself.
Apply it
A fluid-overloaded patient with AKI produces more urine after a loop diuretic but still has worsening acidosis and refractory hyperkalemia. Evaluate those complications independently; the improved urine volume does not demonstrate sufficient recovery or eliminate replacement therapy needs.
Common pitfall: Urine output is not equivalent to solute clearance. Pursuing larger diuretic doses solely to improve the output number can distract from persistent physiological deterioration.
KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Allocate the largest study block to CKD, including substantial dialysis and mineral-bone work, because CKD accounts for 22% of the blueprint and end-stage renal disease alone accounts for 11.5% of the whole examination.
- Practise AKI mechanisms, staging, emergency replacement indications, and modality selection together; AKI and intensive care nephrology account for 15%.
- Use paired serum and urine data to distinguish antidiuresis, solute diuresis, tubular transport defects, and glomerular injury.
- Separate lesion names from treatment mechanisms: primary versus secondary FSGS, rejection versus BK injury, and hemodynamic change versus structural injury.
- Calculate anion gaps, expected respiratory compensation, percentage creatinine changes, and urine-output stages without relying on reference-range intuition.
- Use the official expanded outline to complete omitted areas, including magnesium disorders, anemia, additional vascular syndromes, detailed PD prescription, living-donor risk assessment, and transplantation ethics.
A practical preparation plan
1. Map the full CERT outline
Read the January 2026 expanded certification blueprint and mark each topic as secure, uncertain, or unstudied. Use its published weights to plan time; treat these 60 concepts as selected decision points within the larger scope.
2. Build physiological comparison tables
Compare hypotonic hyponatremia patterns, RTA phenotypes, nephritic and nephrotic presentations, and AKI compartments. For each comparison, record the discriminating measurement and the tempting alternative it excludes.
3. Give CKD and dialysis repeated practice
Work through CGA classification, kidney-protective therapy, dialysis initiation, delivered adequacy, access dysfunction, water safety, volume management, PD infection, and CKD-MBD trends. Extend study to the prescription and complication topics in the full outline.
4. Rehearse calculations and urgent decisions
Calculate anion gaps, Winter's expected carbon dioxide, creatinine percentage changes, and weight-based urine output. Then decide whether a case requires reassessment, biopsy, medical stabilization, or urgent kidney replacement therapy.
5. Use the drills diagnostically
Answer the 20 questions before reading explanations. For every error, identify the missed cue and explain why each alternative fails. These short drills identify study needs and do not predict certification performance.
6. Space recall and verify administration details
Review flashcards at increasing intervals and revisit weak domains with primary guidance. Before the examination, confirm current registration, timing, and delivery instructions directly with ABIM.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABIM — Blueprints
- ABIM Nephrology Blueprint — Certification Examination (CERT), January 2026
- ABIM — Nephrology Certification Policies
- ABIM — Register, Prepare and Take Your Nephrology Certification Exam
- Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia, 2014
- Endotext — Diagnostic Testing for Diabetes Insipidus
- Mayo Clinic — Nephrology: Acid-Base, 2022
- NIDDK — Renal Tubular Acidosis
- EAU Guidelines on Urolithiasis — Metabolic Evaluation and Recurrence Prevention
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
- KDIGO — CKD Evaluation and Management
- ISPD Peritonitis Guideline Recommendations: 2022 Update on Prevention and Treatment
- Endocrine Society — Primary Aldosteronism Clinical Practice Guideline, 2025
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD
- KDIGO 2025 Clinical Practice Guideline for ADPKD
- KDIGO 2021 — Key Takeaways for Anti-GBM Glomerulonephritis
- KDIGO 2021 — Key Takeaways for Membranous Nephropathy
- KDIGO 2021 — Key Takeaways for FSGS
- KDIGO 2021 — Key Takeaways for Minimal Change Disease in Adults
- KDIGO 2009 Kidney Transplant Recipient Guideline — Summary
- Second International Consensus Guidelines on BK Polyomavirus in Kidney Transplantation, 2024
- DailyMed — Tacrolimus Capsules Prescribing Information
- KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury
- KDIGO — Acute Kidney Injury and Acute Kidney Disease
- KDIGO — Summary of 2017 CKD-MBD Guideline Recommendations
- NIDDK — Keeping Kidneys Safe: Smart Choices about Medicines
- Utility of Urine Eosinophils in the Diagnosis of Acute Interstitial Nephritis - PMC
- 62nd-Edition-of-The-Grey-Book.pdf
- 2019-kdoqi-guideline-vascular-access.pdf
- KDIGO-2024-ANCA-Vasculitis-Guideline-Update.pdf
- KDIGO-Txp-Candidate-GL-FINAL.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.